Lammers J W, Kioumis I, McCusker M, Nichol G M, Barnes P J, Chung K F
Department of Thoracic Medicine, Brompton Hospital, London, England.
J Allergy Clin Immunol. 1990 Apr;85(4):763-9. doi: 10.1016/0091-6749(90)90196-b.
We studied the effects of prostacyclin (PGI2) on the airway responses to platelet-activating factor (PAF) in a randomized and crossover study in eight normal subjects. PGI2 or diluent (glycine buffer) was continuously infused on 2 separate days. Two breaths of PAF (21 micrograms) were inhaled three times every 15 minutes and airflow at 30% of vital capacity from partial flow-volume curves (Vp30) was measured. PGI2 (4 ng/kg/min) had no effect on Vp30 or blood pressure, whereas heart rate increased from 70.3 +/- 3.9 to 73.7 +/- 4.0 beats/min (mean +/- SEM; p less than 0.01). Two subjects did not complete the study because of transient hypotension. PGI2 had no effect on PAF-induced bronchoconstriction with maximal decreases in Vp30 of 42.0 +/- 8.0% (p less than 0.01) during PGI2 and 49.8 +/- 14.2% (p less than 0.02) during diluent infusion. Ex vivo platelet aggregation to PAF (10(-9) to 10(-7) mol/L) was significantly inhibited by PGI2. Circulating neutrophils decreased from 4.7 +/- 0.9 x 10(9)/L to 1.5 +/- 0.3 x 10(9)/L (p less than 0.05) 5 minutes after the first PAF inhalation during diluent infusion, whereas there was no significant change with PGI2. Thus, PGI2 does not influence PAF-induced bronchoconstriction in man despite causing marked inhibition of ex vivo PAF-induced platelet aggregation and preventing the fall of neutrophils.
在一项针对8名正常受试者的随机交叉研究中，我们研究了前列环素（PGI2）对气道对血小板活化因子（PAF）反应的影响。在两个不同的日子里持续输注PGI2或稀释剂（甘氨酸缓冲液）。每隔15分钟吸入两次PAF（21微克），共三次，并根据部分流速-容量曲线（Vp30）测量肺活量30%时的气流。PGI2（4纳克/千克/分钟）对Vp30或血压无影响，而心率从70.3±3.9次/分钟增加到73.7±4.0次/分钟（平均值±标准误；p<0.01）。两名受试者因短暂性低血压未完成研究。PGI2对PAF诱导的支气管收缩无影响，在输注PGI2期间Vp30最大降低42.0±8.0%（p<0.01），在输注稀释剂期间为49.8±14.2%（p<0.02）。PGI2显著抑制了体外血小板对PAF（10^(-9)至10^(-7)摩尔/升）的聚集。在输注稀释剂期间，首次吸入PAF后5分钟，循环中性粒细胞从4.7±0.9×10^9/升降至1.5±0.3×10^9/升（p<0.05），而使用PGI2时无显著变化。因此，尽管PGI2能显著抑制体外PAF诱导的血小板聚集并防止中性粒细胞减少，但它并不影响人类体内PAF诱导的支气管收缩。
